Advestra on Ironwood’s USD1B Cash Tender Offer for VectivBio

Ironwood Pharmaceuticals (Nasdaq: IRWD), a healthcare company specializing in GI treatments, and VectivBio Holding (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe rare gastrointestinal conditions, have reached an agreement where Ironwood will initiate an all-cash public tender offer to acquire VectivBio at a price of USD17.00 per share. The estimated total consideration for the transaction is approximately USD1 billion, taking into account VectivBio’s cash and debt. 

Advestra advised Iron­wood on the Swiss leg­al and tax aspects of this trans­ac­tion. The team included Daniel Raun (pictured), Andreas Hin­sen, Anna Tomaschek, Anna Capaul, Fabi­an Wild, Samuel Fäh and Akira Kimati (all cor­por­ate | M&A) as well as Céline Mar­tin, Laurent Ried­weg and Philip Frey (all tax). 

Homburger served as legal and tax advisor to VectivBio on the transaction. Click here for the team details.